CoChat
Sign Up
Cited by 56

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Fungal infections in immunocompromised critically ill patients

Garnacho-Montero, José, Barrero-García, Irene, León-Moya, Cristina·2024·Journal of Intensive Medicine
DOI 10.1016/j.jointm.2024.01.005PMC PMC11258510
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jointm.2024.01.005

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 69

  1. Azoulay, 2017, The intensive care medicine research agenda on critically ill oncology and hematology patients, Intensive Care Medicine, 43, 1366, 10.1007/s00134-017-4884-z · DOI
  2. Cantón-Bulnes, 2022, Determinants of mortality in cancer patients with unscheduled admission to the Intensive Care Unit: a prospective multicenter study, Medicina Intensiva, 46, 669, 10.1016/j.medin.2021.08.005 · DOI
  3. Azoulay, 2017, Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study, Intensive Care Medicine, 43, 1808, 10.1007/s00134-017-4947-1 · DOI
  4. Azoulay, 2020, Diagnosis of severe respiratory infections in immunocompromised patients, Intensive Care Medicine, 46, 298, 10.1007/s00134-019-05906-5 · DOI
  5. Koulenti, 2014, Approach to invasive pulmonary aspergillosis in critically ill patients, Current Opinion in Infectious Diseases, 27, 174, 10.1097/QCO.0000000000000043 · DOI
  6. Garnacho-Montero, 2013, Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient, Revista Española de Quimioterapia, 26, 173
  7. Hamam, 2021, New clinical algorithm including fungal biomarkers to better diagnose probable invasive pulmonary aspergillosis in ICU, Annals of Intensive Care, 11, 41, 10.1186/s13613-021-00827-3 · DOI
  8. Rozaliyani, 2021, Molecular typing and antifungal susceptibility study of Aspergillus spp. in intensive care unit (ICU) patients in Indonesia, The Journal of Infection in Developing Countries, 15, 1014, 10.3855/jidc.13135 · DOI
  9. Ascioglu, 2002, Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus, Clinical Infectious Diseases, 34, 7, 10.1086/323335 · DOI
  10. Bassetti, 2021, EORTC/MSGERC definitions of invasive fungal diseases: summary of activities of the intensive care unit working group, Clinical Infectious Diseases, 72
  11. Estella, 2022, Pulmonary aspergillosis in the intensive care unit: an underdiagnosed disease, Medicina Intensiva, 46, 423, 10.1016/j.medin.2022.02.011 · DOI
  12. Lamoth, 2024, Lung and sinus fungal infection imaging in immunocompromised patients, Clinical Microbiology and Infection, 30, 296, 10.1016/j.cmi.2023.08.013 · DOI
  13. Greene, 2005, The radiological spectrum of pulmonary aspergillosis, Medical Mycology, 43, S147, 10.1080/13693780500064771 · DOI
  14. Alexander, 2021, Guidance on imaging for invasive pulmonary aspergillosis and mucormycosis: from the imaging working group for the revision and update of the consensus definitions of fungal disease from the EORTC/MSGERC, Clinical Infectious Diseases, 72
  15. Estella, 2023, Microbiological diagnosis of pulmonary invasive aspergillosis in critically ill patients with severe SARS-CoV-2 pneumonia: a bronchoalveolar study, Annals of Clinical Microbiology and Antimicrobials, 22, 90, 10.1186/s12941-023-00626-7 · DOI
  16. Meersseman, 2008, Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients, The American Journal of Respiratory and Critical Care Medicine, 177, 27, 10.1164/rccm.200704-606OC · DOI · Paper page
  17. Onishi, 2012, Diagnostic accuracy of serum 1,3-β-d-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis, The Journal of Clinical Microbiology, 50, 7, 10.1128/JCM.05267-11 · DOI
  18. Azoulay, 2016, (1, 3)-β-d-glucan assay for diagnosing invasive fungal infections in critically ill patients with hematological malignancies, Oncotarget, 7, 21484, 10.18632/oncotarget.7471 · DOI
  19. Singh, 2022, The comparative evaluation of the fujifilm wako β-glucan assay and fungitell assay for diagnosing invasive fungal disease, Journal of Fungi (Basel), 9
  20. De Carolis, 2020, Comparative performance evaluation of Wako β-glucan test and Fungitell assay for the diagnosis of invasive fungal diseases, PLoS One, 15, 10.1371/journal.pone.0236095 · DOI
  21. Townsend, 2022, Invasive aspergillosis in the intensive care unit, Diagnostics (Basel), 12, 2712, 10.3390/diagnostics12112712 · DOI
  22. Mercier, 2021, Defining galactomannan positivity in the updated EORTC/MSGERC consensus definitions of invasive fungal diseases, Clinical Infectious Diseases, 72
  23. Ullmann, 2018, Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline, Clinical Microbiology and Infection, 24
  24. Dobiáš, 2023, Current and future pathways in aspergillus diagnosis, Antibiotics (Basel), 12
  25. Jenks, 2020, The Aspergillus lateral flow assay for the diagnosis of invasive aspergillosis: an update, Current Fungal Infection Reports, 14, 378, 10.1007/s12281-020-00409-z · DOI
  26. Jenks, 2021, Performance of the bronchoalveolar lavage fluid Aspergillus Galactomannan lateral flow assay with cube reader for diagnosis of invasive pulmonary aspergillosis: a multicenter cohort study, Clinical Infectious Diseases, 73, 10.1093/cid/ciaa1281 · DOI
  27. Baddley, 2013, Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes, BMC Infectious Diseases, 13, 29, 10.1186/1471-2334-13-29 · DOI
  28. Patterson, 2016, Executive summary: practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the infectious diseases society of America, Clinical Infectious Diseases, 63, 433, 10.1093/cid/ciw444 · DOI
  29. Douglas, 2021, Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021, The Internal Medicine Journal, 51, 143, 10.1111/imj.15591 · DOI
  30. Garcia-Vidal, 2019, Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 update by the GEMICOMED-SEIMC/REIPI, Enfermedades Infecciosas y Microbiología Clínica, 37, 535, 10.1016/j.eimc.2018.03.018 · DOI
  31. Pardo, 2019, Invasive pulmonary aspergillosis in critically ill patients with hematological malignancies, Intensive Care Medicine, 45, 1732, 10.1007/s00134-019-05789-6 · DOI
  32. Burghi, 2011, Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis, Intensive Care Medicine, 37, 1605, 10.1007/s00134-011-2344-8 · DOI
  33. Maertens, 2016, Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial, Lancet, 387, 760, 10.1016/S0140-6736(15)01159-9 · DOI · Paper page
  34. Maertens, 2021, Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial, Lancet, 397, 499, 10.1016/S0140-6736(21)00219-1 · DOI
  35. Risum, 2021, Therapeutic drug monitoring of isavuconazole: serum concentration variability and success rates for reaching target in comparison with voriconazole, Antibiotics (Basel), 10, 487, 10.3390/antibiotics10050487 · DOI
  36. Höhl, 2022, Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis, Mycoses, 65, 747, 10.1111/myc.13469 · DOI
  37. Perez, 2023, Population pharmacokinetics of isavuconazole in critical care patients with COVID-19-associated pulmonary aspergillosis and Monte Carlo simulations of high off-label doses, Journal of Fungi (Basel), 9, 211, 10.3390/jof9020211 · DOI
  38. Sokulska, 2015, Pneumocystis jirovecii–from a commensal to pathogen: clinical and diagnostic review, Parasitology Research, 114, 3577, 10.1007/s00436-015-4678-6 · DOI
  39. Schmidt, 2018, Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years, Critical Care, 22, 307, 10.1186/s13054-018-2221-8 · DOI
  40. Giacobbe, 2023, Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG, Critical Care, 27, 323, 10.1186/s13054-023-04608-1 · DOI
  41. Quist, 1995, Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia, Chest, 108, 415, 10.1378/chest.108.2.415 · DOI
  42. Azoulay, 2009, Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates, Chest, 135, 655, 10.1378/chest.08-1309 · DOI
  43. Bigot, 2022, Usefulness of ß-D-glucan assay for the first-line diagnosis of pneumocystis pneumonia and for discriminating between pneumocystis colonization and pneumocystis pneumonia, Journal of Fungi (Basel), 8, 663, 10.3390/jof8070663 · DOI
  44. Fauchier, 2016, Detection of pneumocystis jirovecii by quantitative PCR to differentiate colonization and pneumonia in immunocompromised HIV-positive and HIV-negative patients, The Journal of Clinical Microbiology, 54, 1487, 10.1128/JCM.03174-15 · DOI
  45. Maschmeyer, 2016, ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients, The Journal of Antimicrobial Chemotherapy, 71, 2405, 10.1093/jac/dkw158 · DOI
  46. Sun, 2014, Efficacy of caspofungin, a 1,3-β-d-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats, Medical Mycology, 52, 798, 10.1093/mmy/myu060 · DOI
  47. Lobo, 2013, Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice, PLoS One, 8, e70619, 10.1371/journal.pone.0070619 · DOI
  48. Huang, 2022, Infectious Diseases and Therapy, 11, 543, 10.1007/s40121-021-00586-5 · DOI
  49. Qi, 2023, Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection, BMC Infectious Diseases, 23, 409, 10.1186/s12879-023-08372-z · DOI
  50. Koehler, 2023, Which trial do we need? Combination treatment of Pneumocystis jirovecii pneumonia in non-HIV infected patients, Clinical Microbiology and Infection, 29, 1225, 10.1016/j.cmi.2023.05.004 · DOI
  51. Ewald, 2015, Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection, The Cochrane Database of Systematic Reviews, 2015, 10.1002/14651858.CD006150.pub2 · DOI
  52. Ghrenassia, 2019, Candidemia in critically ill immunocompromised patients: report of a retrospective multicenter cohort study, Ann Intensive Care, 9, 62, 10.1186/s13613-019-0539-2 · DOI
  53. Lortholary, 2017, The risk and clinical outcome of candidemia depending on underlying malignancy, Intensive Care Medicine, 43, 652, 10.1007/s00134-017-4743-y · DOI
  54. Cristina, 2023, An overview on Candida auris in healthcare settings, Journal of Fungi (Basel), 9, 913, 10.3390/jof9090913 · DOI
  55. Kontoyiannis, 2002, Pulmonary candidiasis in patients with cancer: an autopsy study, Clinical Infectious Diseases, 34, 400, 10.1086/338404 · DOI
  56. Alves, 2022, How to identify invasive Candidemia in ICU-A narrative review, Antibiotics (Basel), 11, 1804, 10.3390/antibiotics11121804 · DOI
  57. León, 2012, Value of β-d-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions, Intensive Care Medicine, 38, 1315, 10.1007/s00134-012-2616-y · DOI
  58. Clancy, 2018, Detecting infections rapidly and easily for Candidemia Trial, part 2 (DIRECT2): a prospective, multicenter study of the T2 Candida Panel, Clinical Infectious Diseases, 66, 1678, 10.1093/cid/cix1095 · DOI · Paper page
  59. Taur, 2010, Effect of antifungal therapy timing on mortality in cancer patients with candidemia, Antimicrob Agents Chemother, 54, 184, 10.1128/AAC.00945-09 · DOI · Paper page
  60. Martin-Loeches, 2019, ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients, Intensive Care Medicine, 45, 789, 10.1007/s00134-019-05599-w · DOI
  61. Pappas, 2016, Clinical practice guideline for the management of Candidiasis: 2016 update by the infectious diseases society of America, Clinical Infectious Diseases, 62, e1, 10.1093/cid/civ933 · DOI · Paper page
  62. Tang, 2023, Efficacy and safety of echinocandin monotherapy and combination therapy for immunocompromised patients with systemic candidiasis: a systematic review and meta-analysis, Journal de Mycologie Médicale, 33, 10.1016/j.mycmed.2023.101362 · DOI
  63. Syed, 2023, Rezafungin: first approval, Drugs, 83, 833, 10.1007/s40265-023-01891-8 · DOI
  64. De Pascale, 2020, (1,3)-β-d-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial, Critical Care, 24, 550, 10.1186/s13054-020-03265-y · DOI
  65. Rouzé, 2017, Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial, Intensive Care Medicine, 43, 1668, 10.1007/s00134-017-4932-8 · DOI
  66. Skiada, 2018, Challenges in the diagnosis and treatment of mucormycosis, Medical Mycology, 56, 93, 10.1093/mmy/myx101 · DOI
  67. Kontoyiannis, 2016, A potential explanation of a positive serum β-glucan assay in mucormycosis, Open Forum Infectious Diseases, 3, ofw209, 10.1093/ofid/ofw209 · DOI
  68. Cornely, 2019, Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the Mycoses study group education and research consortium, The Lancet Infectious Diseases, 19, 10.1016/S1473-3099(19)30312-3 · DOI
  69. Marty, 2016, Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis, The Lancet Infectious Diseases, 16, 828, 10.1016/S1473-3099(16)00071-2 · DOI

Cited by

Sorted by citations

See all 56

Metadata

Authors
Garnacho-Montero, J., Barrero-García, I., & León-Moya, C.
Venue
Journal of Intensive Medicine
Publisher
Elsevier BV
Published
2024-07
Volume
4
Issue
3
Pages
299-306
ISSN
2667-100X
DOI
10.1016/j.jointm.2024.01.005
PMC
PMC11258510
Cited by
56
References
7
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review